Background: The modified Marsh and Schnider pharmacokinetic models for propofol consistently produce negatively and positively biased predictions in underweight patients, respectively. We aimed to develop a new pharmacokinetic model of propofol in underweight patients. Methods: Twenty underweight (BMI<18.5 kg m À2 ) patients aged 20e68 yr were given an i.v. bolus of propofol (2 mg kg
Low body mass index (BMI) can result from malnutrition, underlying health conditions such as malignancy, and psychological factors in adults.
1,2 'Low body weight' is a term used to simply describe that a person's weight is low, whereas the definition of 'underweight' usually refers to a person whose weight is low for their height (BMI<18.5 kg m À2 ). 3 In a previous study, about 2.4% of patients undergoing major intraabdominal cancer surgery were underweight. 4 The modified Marsh model and the Schnider model are two models commonly used to administer propofol via targetcontrolled infusion (TCI), 5 and these two models alone have been embedded in the commercially available TCI pumps in Korea. In our previous study, the predictive performance of these two models in the target effect-site concentration (Ce) range of 2e6 mg ml À1 was evaluated in underweight patients. 6 The pooled median (95% confidence interval) biases and inaccuracies at a target Ce 3 mg ml À1 were À22.6% (À28.8% to À12.6%) and 31.9%
(24.8e36.8%) for the modified Marsh model. These values at Ce!4 mg ml À1 were 19.8% (12. 9e25.7%) and 36.2% (31.4e39.7%) for the Schnider model. 6 The clinically acceptable range for pooled inaccuracies in pharmacokinetic predictions of propofol is approximately 20e30%. 7e9 Those of the modified Marsh and
Schnider models failed to meet these criteria within a specific target Ce range. Also, the modified Marsh and Schnider models consistently produced negatively and positively biased predictions, respectively. This may suggest that use of the modified Marsh and Schnider models can lead to inadvertent underdosing and overdosing of propofol in underweight patients. In another retrospective study of ours, general anaesthesia was maintained at a propofol target Ce of 2.5e3 mg ml À1 using the modified Marsh model, and the amount of i.v. midazolam and mean infusion rate of remifentanil during anaesthesia were significantly higher in underweight patients than in normal weight patients. 10 Unfortunately, the Eleveld model, performed for a wide range of patient groups and clinical conditions, 11 showed similar predictive performance to the modified Marsh and Schnider models. 6 The aim of this study was to develop a new pharmacokinetic model for TCI of propofol to underweight patients. In addition, the time to peak effect for calculating the blood brain equilibration rate constant (k e0 ) was measured in another a second underweight patients group.
Methods

Investigation drug
Propofol, formulated in a mixture of medium-and long-chain triglycerides (Propofol-MCT/LCT 1%, Freefol-MCT ® ; Daewon Pharmaceutical Co Ltd, Seoul, Korea), was used in this study.
Patient population
This prospective clinical trial was conducted from September 2015 to April 2016. The study protocol was approved by the Institutional Review Board of Asan Medical Centre (2015À0957, Seoul, Korea) and registered on an international clinical trials registry platform (http://cris.nih.go.kr; KCT0001760). Twenty ASA physical status 1 or 2 underweight patients who were undergoing elective surgery were enrolled in the pharmacokinetic model building. The patient exclusion criteria included a known allergy to propofol, a preoperative haemoglobin level <9 g dl À1 , clinically significant laboratory findings, and evidence of pregnancy.
Procedure
All of the patients fasted from midnight on the day of surgery, without premedication. Once in the operating theatre, they were monitored using pulse oximetry, electrocardiography, end-tidal carbon dioxide partial pressure, NIBP (Carescape™ Monitor B850; GE Healthcare, Chicago, IL, USA), and the bispectral index (BIS ® monitor; Covidien, Boulder, CO, USA). All data were recorded continuously until the end of anaesthesia. A 20-gauge angiocatheter was placed in the radial artery for frequent blood sampling. During pre-oxygenation using a face mask with oxygen 100%, lidocaine 20 mg was i.v. administered before propofol injection. Subsequently, an i.v. bolus of propofol 2 mg kg À1 was given to patients. Five minutes later, a zero-order infusion of propofol was started at a rate of 8 mg kg À1 h À1 until the end of surgery and remifentanil was administered via target Ce-controlled infusion using the Minto model. 12 If necessary, midazolam was administered to maintain BIS values less than 60 during anaesthesia maintenance. The target Ce of remifentanil was titrated to maintain stable haemodynamics (systolic BP>80 mm Hg and heart rate>45 beats min À1 ) within the range of 2e20 ng ml À1 . Tracheal intubation was facilitated by administration of rocuronium 0.6 mg kg
À1
. The patients were then ventilated with oxygen in air (1:2), and the ventilation rate was adjusted to maintain an endtidal carbon dioxide partial pressure of 35e45 mm Hg. If necessary, ephedrine was administered to maintain stable haemodynamics. Infusions of propofol and remifentanil were terminated at the onset of skin suture. Neuromuscular block was antagonised via the administration of neostigmine and glycopyrrolate at the end of surgery.
Blood sampling and plasma concentration assay
Arterial blood samples (5 ml) were obtained at preset intervals: 0, 0.5, 1, 1.5, 3, and 5 min after a bolus dose of propofol; 5, 10, 20, 40, 60, 90, and 120 min after continuous infusion of propofol; and 0, 5, 10, and 30 min and 1, 2, 6, 12, and 24 h after discontinuation of propofol infusion. Additionally, arterial blood samples were also obtained at the time to loss of responsiveness (LOR) and recovery of responsiveness (ROR). Time to LOR was determined every 5 s after the bolus injection of propofol via the loss of response to a verbal command (open your eyes). Time to ROR was assessed every 30 s after discontinuation of propofol via the eyes opening in response to a verbal command. 13 Each blood sample was collected in a tube containing ethylenediaminetetraacetic acid and centrifuged for 10 min at 252 Â g; the plasma was stored at À70 C until required for the assay. Plasma concentrations of propofol were analysed using ultrafast lipid chromatography (Shimadzu, Kyoto, Japan) 
Population pharmacokinetics
A population pharmacokinetic analysis was performed with NONMEM VII level 3 (ICON Development Solutions, Ellicott City, MD, USA). Plasma propofol concentrations were fitted to one-, two-, or three-compartment models using the ADVAN 6 subroutines and first-order conditional estimation with interaction.
Inter-individual random variabilities of pharmacokinetic parameters were estimated assuming a log-normal distribution. Diagonal matrices were estimated for the various distributions of h, where h represents inter-individual random variability with a mean of zero and variance of u.
2 Additive and constant coefficients of variation and combined additive and constant coefficient of variation residual error models were evaluated during the model building process. NONMEM computed the minimum objective function value (OFV), a statistical equivalent to the À2 log likelihood of the model. An a level of 0.05, which corresponds to a reduction in the OFV of 3.84 (c 2 distribution, degree of freedom¼1, P<0.05), was used to distinguish between hierarchical models. 14 The covariates analysed were age, sex (0¼female, 1¼male), total body weight (TBW), height, body surface area, 15 BMI, ideal body weight, 16 and lean body mass (LBM). 17 Non-parametric bootstrap analysis served to validate the models internally (fit4NM 3.3.3, Eun-Kyung Lee and GyuJeong Noh; http://cran.r-project.org/web/packages/fit4NM/ index.html; last accessed: March 16, 2011). 18 Predictive checks were also performed using fit4NM 3.3.3.
19
Time to peak effect (t peak )
An additional 33 ASA PS 1 or 2 underweight patients undergoing elective surgery under general anaesthesia were enrolled for the estimation of the k e0 of the pharmacokinetic model. An i.v. bolus of propofol 2 mg kg À1 was administered after i.v. lidocaine pretreatment. The bolus doses were administered manually by skilled nurses at a rate of 2 ml s
À1
. Five minutes later, propofol and remifentanil were administered by target Ce-controlled infusion (Asan Pump, version 2.1.3; Bionet Co Ltd, Seoul, Korea) using the Schnider and Minto models. 12, 20 The initial target concentrations of propofol and remifentanil were 2.5 mg ml À1 and 3 ng ml
, respectively. The time to peak effect, defined as the time delay between the bolus injection of propofol and the maximally reduced BIS from the baseline value, was observed. Time to lowest BIS after an initial bolus was determined from the individual data file of BIS. BIS values were calculated with a smoothing rate of 15 s and were collected at 5-s intervals on a laptop computer for offline analysis.
Simulations
Deterministic simulations were performed using Asan Pump version 2. 
Results
Population pharmacokinetics
The study patient characteristics are summarised in Table 1 . In total, 455 plasma samples obtained from 20 underweight patients were used to build a pharmacokinetic model. The plasma concentrations of propofol over time are shown in Figure 1A . pharmacokinetics of propofol in underweight patients. Parameter estimates of the competing base and covariate pharmacokinetic models of propofol are described in the Supplementary material (Table S1 ). BMI was a significant covariate for the rapid peripheral volume of distribution. LBM was also a significant covariate for metabolic clearance and the inter-compartmental clearance of the slow peripheral compartment. The relationship between individual Bayesian predicted values of pharmacokinetic parameters and body size parameters are presented in the Supplementary material (Fig. S1 ). Table 2 presents the population pharmacokinetic parameter estimates and the results of non-parametric bootstrap replicates of the final pharmacokinetic model of propofol. Goodness-of-fit plots of the final pharmacokinetic model of propofol are presented in Figure 1B and D. Predictive checks of the final pharmacokinetic model are presented in Figure 2 . The percentage of data distributed outside the 95% prediction intervals of the final pharmacokinetic model was 5.9%, indicating that the final model adequately described the time courses of plasma propofol concentration.
Time to peak effect
Of the 33 underweight patients enrolled in the estimation of the k e0 for the pharmacokinetic model, five were excluded from the analysis because of a technical error in BIS file storage (n¼2) or a failure to observe a definite peak effect (n¼3). Thus, after the addition of the 20 patients enrolled in the pharmacokinetic model building, 48 underweight patients were analysed to calculate the k e0 . The time course of BIS values after an i.v. bolus injection of propofol 2 mg kg À1 is shown in Figure 3 .
The median (25e75%) value of the time to the maximally reduced BIS from baseline was 1.32 (1.07e2.03) min.
Simulation
Simulated cumulative doses and infusion rates over time to maintain a target Cp of 2.5 mg ml À1 for 60 min for several models are presented in Figure 4A and 4B. The Schnider, Choi, modified Marsh, and Eleveld models are ranked in order of cumulative dose at 60 min after infusion. The same results were obtained with the fast-infusion rate sequence. Simulated Cp based on the modified Marsh, Schnider, and Eleveld models using an infusion profile to maintain a target Cp of 2.5 mg ml
À1
for 60 min using the Choi model are shown in Figure 4C . current study, BMI was found to be a significant covariate of the rapid peripheral volume of distribution, which may be explained by the physical characteristics of underweight patients. As mentioned previously, the term 'underweight' is used to describe individuals whose TBW is considered too low for their height. From the perspective of body composition, underweight patients show a significant reduction in fat mass and fat-free mass compared with normal weight patients. 25 In previous studies, BMI was a significant covariate on volume of distribution. 26, 27 The inclusion of BMI as a covariate of the rapid peripheral volume of distribution led to a greater improvement in the OFV (9.02) than the inclusion of TBW (6.69) or LBM (0.87). We showed that as the LBM increased, the metabolic clearance and inter-compartmental clearance of the slow peripheral compartment increased (see Supplementary Fig. S1 ), which was consistent with previous results showing that LBM was a significant covariate in metabolic clearance. 12, 20 Propofol dosing based on a scale that is linearly related to TBW leads to overdosing of obese patients and underdosing of paediatric patients because the relationship between drug clearance and TBW is non-linear. 28 In addition, allometric or LBM scaling of propofol pharmacokinetics may be applicable to a wide range of patients ranging from children to obese adults. 28 An allometric pharmacokinetic model can predict propofol concentration well for a wide range of patient ages and weights. 11 However, the allometric scale approach was not applied in this study for three reasons. First, there was no evidence that allometric scaling works well in an extreme group of patients, such as underweight patients. Second, the Eleveld model with allometric scaling did not perform well in underweight patients. 6 Third, Akaike information criteria (AIC) of the allometric model was not better than the final pharmacokinetic model (difference from AIC of base model: 23.40 for allometric model, 24.31 for Choi model). When LBM calculated by the James equation is Table 2 Population pharmacokinetic parameter estimates, inter-individual variability, and median parameter values (2.5e97.5%) of the non-parametric bootstrap replicates of the basic and final pharmacokinetic models of propofol in underweight patients. A lognormal distribution of inter-individual random variability was assumed. Residual random variability was modelled using an additive (s 1 ) plus proportional (s 2 ) error model. Non-parametric bootstrap analysis was repeated 2000 times. Cl, metabolic clearance; LBM, lean body mass calculated using the Janmahasatian formula; 17 Q 1 , inter-compartmental clearance of the rapid peripheral compartment; Q 2 , inter-compartmental clearance of the slow peripheral compartment; RSE, relative standard error¼SE/meanÂ100 (%); V 1 , central volume of distribution; V 2 , rapid peripheral volume of distribution; V 3 , slow peripheral volume of distribution Pharmacokinetic propofol models in underweight patients -563 plotted against body weight, an inverted parabolic function is created, which may lead to incorrect results. 29, 30 In the present study, LBM, determined using the Janmahasatian formula, 17 was used to build the covariate models. Our previous study showed that target Ce-controlled infusion of propofol driven by the modified Marsh and Schnider models can lead to underdosing and overdosing in underweight patients, respectively. 6 As demonstrated in Figure 4 , the simulated dose requirement to maintain a target plasma concentration of 2.5 mg ml À1 for 60 min in the Choi model (349.6 mg) was about halfway between the modified Marsh (318.2 mg) and Schnider (435.8 mg) models, indicating that the Choi model may provide appropriate dosing when underweight patients receive propofol via target Ce-controlled infusion. In the same hypothetical person, the simulated dose requirement to maintain a target plasma concentration of 5 mg ml À1 for 60 min in the Choi, modified Marsh and Schnider models were 699.2 mg, 635.8 mg, and 871.6 mg, respectively. In TCI, doubling the target concentration will double the dose administration because the infusion algorithm of TCI is based on linear pharmacokinetics. 31 The pharmacokinetics of propofol are linear over a large dosage range. 20 Although target Ce-controlled infusion of propofol using the Choi model may be applicable to underweight patients, a predictive performance evaluation of this model is required before its use in clinical practice. In general, target Ce-controlled infusion is mainly used instead of target plasma concentration-controlled infusion because the former can ensure prompter onset and titration of hypnotics and/or analgesics in response to surgical stress during anaesthesia. For target Ces, a TCI system should incorporate pharmacokinetic parameters and the bloodebrain equilibration rate constant (k e0 ). 5, 32 The k e0 can be estimated in two ways. First, an integrated pharmacokinetic/pharmacodynamics modelling technique should be used in a single population, which is the standard method. Second, a modelindependent time to peak effect (t peak ) can estimate the k e0 , which can be used when pharmacodynamic and pharmacokinetic data are not available for the same population group. 5 Because propofol has no analgesic effect, analgesics such as remifentanil should be administered concomitantly during general anaesthesia. Propofol and remifentanil have been reported to have an interactive effect on the central nervous system. 33, 34 It was difficult to perform the integrated pharmacokinetic/pharmacodynamics modelling of propofol in Eleveld models in a hypothetical underweight patient. Simulated Cp (C) based on the modified Marsh, Schnider, and Eleveld models using an infusion profile to maintain a target Cp of 2.5 mg ml À1 for 60 min using the Choi model. Weight, height, age, and sex were assumed to be 45 kg, 170 cm, 40 yr, and female, respectively. In the Eleveld model, the pharmacokinetic parameters for the patient were used in the simulation process.
patients under general anaesthesia. For this reason, the k e0 was estimated using the t peak method in this study. The k e0 is 0.2792 min À1 for a hypothetical underweight female patient with an age, body weight, and height of 40 yr, 45 kg, and 170 cm, respectively. One 'arm-brain circulation time' of propofol is known to be less than 1 min. 35 A t peak of 1.32 min is seen as a physiologically acceptable value. In previous studies, the estimated t peak was 1.6 min, 22, 23 which is somewhat different from that found in this study. This discrepancy may be explained by differences in patient characteristics and propofol formulations. The mean t peak values measured using the BIS data in Chinese children and adult patients were 1.08 and 1.23 min, respectively. 36, 37 The median value of the time to a maximally reduced BIS from baseline after injection of an i.v. bolus of 1 mg kg À1 microemulsion propofol was 1.68 min. 38 One limitation of this study is that the pharmacokinetic modelling was conducted in surgical patients. To exclude various factors affecting the plasma concentrations of propofol, including surgical stress, anaesthetics and fluid volume, and blood loss, a pharmacokinetic study of propofol should be conducted in healthy volunteers. In fact, there are differences in the pharmacokinetic parameters of propofol between healthy volunteers and patients. 11 However, it is practically impossible to enrol underweight adults as volunteers. It is also unethical in some respects. For this reason, this study was conducted on underweight patients undergoing elective surgeries. Additionally, concomitant medication including remifentanil may directly and indirectly influence the pharmacokinetics of propofol. However, previous studies have shown that propofol affects the pharmacokinetic characteristics of remifentanil, whereas remifentanil does not influence those of propofol. 39 The target concentration at the end of remifentanil TCI was 5.3 (2.5) ng ml
. The synergistic interactive effect of propofol and remifentanil on the LOR was observed in previous studies. 33, 34 It is likely that the ROR values were substantially influenced by the concomitant administration of remifentanil. High concentrations of remifentanil may reduce cardiac output, which may reduce blood flow to the liver, which in turn may affect the clearance of propofol. Because the mean BP was generally well maintained during operation ( Supplementary  Fig. S2 ), propofol clearance may not have decreased.
In conclusion, the time course of plasma propofol concentration is well described by the three-compartment mammillary model. BMI is a significant covariate for the rapid peripheral volume of distribution. LBM is also a significant covariate for both the metabolic clearance and intercompartmental clearance of the slow peripheral compartment in the final pharmacokinetic model of propofol. The median time to a maximally reduced BIS from baseline was 1.32 min. The Choi model can be used to administer propofol via target Ce-controlled infusion in underweight patients within the patient's weight range (29.8e55.5 kg) used for model building. However, a predictive performance evaluation of this model should be performed before its use in clinical practice.
